BioTek

Winooski, United States Founded: 1993 • Age: 33 yrs Acquired By Agilent
Instrumentation and software for microplate-based in-vitro assays are provided.
Annual revenue $7,042 Latest available
Total funding - Funding intelligence
Employees - Tracked headcount
Investors 1 Known backers
Products 3 Services tracked
Competitors 11 Brand Intelligence

About BioTek

BioTek is a company based in Winooski (United States) founded in 1993 was acquired by Agilent in July 2019. BioTek offers products and services including Chromatography Systems, Mass Spectrometry, and Microplate Instrumentation. BioTek operates in a competitive market with competitors including Cellply, Lucid Scientific, Kiyatec, CytoTronics and Saguaro, among others.

  • Headquarter Winooski, United States
  • Stage Public
  • Sectors
    Healthcare
  • Phone
    Locked
  • Website
    Locked
  • Social
    Locked
  • Legal Name Sr Biotek, Inc.
Operational Areas
Healthcare → Biotechnology, Genomics & Life Sciences Research Unlock Sub-Sector Unlock Segment
Key Metrics
  • Annual Revenue
    $7.04 K (USD)
    -93.9
    as on Mar 31, 2023
  • Net Profit
    -$783.32 (USD)
    -102.57
    as on Mar 31, 2023
  • EBITDA
    $666.96 (USD)
    -98.28
    as on Mar 31, 2023
  • Latest Funding Round
    Not available
  • Investors
  • Employee Count
    Not available
  • Acquired by
    Agilent

    (Jul 11, 2019)

Upgrade to premium

Unlock complete access to The Company Check

Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.

Upgrade to Premium No viewing limits. Your plan controls exports and screening usage.
Included in your Premium account
  • Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
  • Full access to every database India & global coverage, advanced filters and rich profile details
  • Always-on access from your team account Single premium plan for everything you see on the portal

IPO & Listings of BioTek

BioTek is a publicly listed company on the KRX with ticker symbol 270210 in South Korea, operating in the Consumer non-durables sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.

Exchange: KRX · Ticker: 270210 · Sector: Consumer non-durables · South Korea

Products & Services of BioTek

BioTek offers a comprehensive portfolio of products and services, including Chromatography Systems, Mass Spectrometry, and Microplate Instrumentation.

Product name locked
Category locked
Primary

Equipment for separating chemical mixtures in laboratories.

Product name locked
Category locked
Locked

Tools for identifying molecules in research applications.

Product name locked
Category locked
Locked

Devices for cell analysis and high-throughput screening.

Funding Insights of BioTek

Premium access

Detailed funding history for BioTek

Round names, dates, amounts, investors, and valuation history require an active premium plan.

  • Round names and dates
  • Funding amounts
  • Participating investors
  • Valuation history

Verified entity values are shown only after access is granted.

Investors in BioTek

BioTek has secured backing from 1 investor, including institutional investors. Prominent investors backing the company include Agilent.

All
Institutional
Investor Description Founded Year Domain Location
Diversified instruments are developed for scientific and laboratory management.
Locked Locked Locked
Premium access

Investor details for BioTek

Investor domains, locations, round participation, and complete history require an active premium plan.

  • Investor domains
  • Investor locations
  • Funding rounds
  • Participation history

Verified entity values are shown only after access is granted.

Investments & Acquisitions by BioTek

Investments
Premium access

Investment portfolio details for BioTek

Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.

  • Portfolio identities
  • Transaction dates
  • Round details
  • Investment values

Verified entity values are shown only after access is granted.

Financial Statements - BioTek

Premium access

Detailed financials for BioTek

Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.

  • Historical revenue
  • Profit trends
  • Statement rows
  • Financial ratios

Verified entity values are shown only after access is granted.

Biotek Comparisons

BioTek Primary company
Description
Instrumentation and software for microplate-based in-vitro a...
Location
Winooski, United States
Founded Year
1993
Annual Revenue
$7.04 K (USD)
Net Profit
-$783.32 (USD)
EBITDA
$666.96 (USD)
Employees
Not available
Premium access

Peer comparison for BioTek

Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.

  • Named peers
  • Headcount comparison
  • Funding comparison
  • Operating benchmarks

Verified entity values are shown only after access is granted.

+
Add Comparison
Available on Premium

Competitors of BioTek

BioTek operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Cellply, Lucid Scientific, Kiyatec, CytoTronics and Saguaro, among others.

Company Name Domain Founded year HQ Location Description
Locked Locked Locked
Developer of in-vitro diagnostic products for the detection of cancer
Locked Locked Locked
Real-time cell analyzers are developed for oxygen consumption monitoring.
Locked Locked Locked
Kiyatec is focused on revolutionizing cancer care through predictive platforms.
Locked Locked Locked
Cell-based assays for drug discovery are developed via CMOS platform.
Locked Locked Locked
3D cell culture products are developed for drug discovery applications.
Locked Locked Locked
Metastatic cancer properties are targeted by Remedy Plan's containment therapy.
Premium access

Detailed competitors of BioTek

Competitor domains, locations, full profiles, and operating metrics require an active premium plan.

  • Domains and locations
  • Full company profiles
  • Operating metrics
  • Competitive positioning

Verified entity values are shown only after access is granted.

Latest news on Biotek

Premium access

Complete news archive for BioTek

Full article history, source details, and older brand coverage require an active premium plan.

  • Full article archive
  • Source and publication date
  • Older coverage
  • Brand-specific news history

Verified entity values are shown only after access is granted.

Frequently Asked Questions about BioTek

BioTek was founded in 1993.

BioTek is headquartered in Winooski, United States. It is registered at Winooski, Vermont, United States.

Briar Alpert is the current CEO of BioTek.

Annual revenue of BioTek is $7.04K as on Mar 31, 2023.

Founded in 1993 and headquartered in Winooski, United States, BioTek focuses on the life sciences sector. Imaging systems, detection instruments, liquid handling tools, robotics, and software for microplate-based in vitro assays are developed and manufactured. Products include automated cell imagers like Lionheart FX, multi-mode readers such as Cytation, washers, dispensers, stackers, and Gen5 software. Applications span cellular and cell-free assays in research settings.

BioTek's top competitors include CytoTronics, Kiyatec and Remedy Plan.

BioTek offers Chromatography Systems, Mass Spectrometry, and Microplate Instrumentation.

Yes, BioTek is publicly traded on KRX under the ticker symbol 270210.

BioTek has 1 investor. Key investors include Agilent.

The ticker symbol of BioTek is 270210 on KRX.

Explore millions of companies — effortlessly

Access structured, verified intelligence on 7M+ companies across industries, sectors, and global markets. From early-stage startups to large enterprises, discover ownership, leadership, funding, financials, acquisitions, and market signals — all in one powerful platform.

Free account with essential features Instant access to company reports Enterprise solutions available